A Phase II Trial of the Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (ICE).

Trial Profile

A Phase II Trial of the Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (ICE).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Ipilimumab (Primary) ; Carboplatin; Etoposide; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ICE
  • Most Recent Events

    • 10 Jun 2016 Primary endpoint has not been met. (To establish the progression free survival at 1 year in patients with extensive stage small cell lung cancer treated with ipilimumab, carboplatin and etoposide.), as per an article published in the Journal of Thoracic Oncology.
    • 10 Jun 2016 Results published in the Journal of Thoracic Oncology
    • 19 Apr 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top